CLINICAL TRIALS PROFILE FOR COUMADIN

All Clinical Trials for COUMADIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003915 ↗	Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment	Completed	Dana-Farber Cancer Institute	Phase 2	2004-03-01	The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: - stop or slow the growth of disease - gain information about prostate cancer - evaluate the effectiveness and side effects of the study drug
NCT00003915 ↗	Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment	Completed	University of Massachusetts, Worcester	Phase 2	2004-03-01	The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: - stop or slow the growth of disease - gain information about prostate cancer - evaluate the effectiveness and side effects of the study drug
NCT00004054 ↗	Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2000-01-01	RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy plus radiation therapy is more effective with or without combination chemotherapy for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy plus radiation therapy with or without combination chemotherapy in treating patients who have prostate cancer.
NCT00004054 ↗	Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer	Completed	Radiation Therapy Oncology Group	Phase 3	2000-01-01	RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy plus radiation therapy is more effective with or without combination chemotherapy for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy plus radiation therapy with or without combination chemotherapy in treating patients who have prostate cancer.
NCT00000469 ↗	Asymptomatic Carotid Artery Plaque Study (ACAPS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	1988-05-01	To determine whether warfarin or lovastatin alone or in combination retarded the progression of atherosclerotic plaques in the carotid arteries of high risk individuals with asymptomatic carotid stenosis. Also, to determine if a full scale trial was feasible.

Clinical Trial Conditions for COUMADIN

Condition Name

Condition Name for COUMADIN
Intervention	Trials
Atrial Fibrillation	23
Healthy	7
Stroke	6
Pulmonary Embolism	6

Condition MeSH

Condition MeSH for COUMADIN
Intervention	Trials
Atrial Fibrillation	30
Thrombosis	24
Venous Thrombosis	17
Thromboembolism	13

Clinical Trial Locations for COUMADIN

Trials by Country

+

−

Trials by Country for COUMADIN
Location	Trials
United States	518
Canada	54
United Kingdom	35
Japan	31
China	31

Trials by US State

+

−

Trials by US State for COUMADIN
Location	Trials
Texas	33
California	24
Florida	21
New York	20
Pennsylvania	19

Clinical Trial Progress for COUMADIN

Clinical Trial Phase

Clinical Trial Phase for COUMADIN
Clinical Trial Phase	Trials
Phase 4	31
Phase 3	23
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for COUMADIN
Clinical Trial Phase	Trials
Completed	85
Recruiting	13
Terminated	11

Clinical Trial Sponsors for COUMADIN

Sponsor Name

Sponsor Name for COUMADIN
Sponsor	Trials
M.D. Anderson Cancer Center	14
Bristol-Myers Squibb	9
Genentech, Inc.	6

Sponsor Type

Sponsor Type for COUMADIN
Sponsor	Trials
Other	183
Industry	73
NIH	15

Coumadin (Warfarin): Clinical Trials, Market Analysis, and Projections

Introduction

Coumadin, commonly known as warfarin, is a vitamin K antagonist that has been a cornerstone in anticoagulation therapy for decades. This article will delve into recent clinical trials, market analysis, and projections for Coumadin, providing a comprehensive overview of its current and future standing in the anticoagulant market.

Clinical Trials: Comparisons with Newer Anticoagulants

Percutaneous Left Atrial Appendage Closure vs Warfarin

A significant clinical trial compared the efficacy of mechanical left atrial appendage closure with warfarin in preventing stroke in patients with atrial fibrillation. The study found that mechanical closure was noninferior to warfarin, with a lower rate of cardiovascular mortality and fewer primary events per 100 patient-years (2.3 vs 3.8)[1].

Direct Oral Anticoagulants (DOACs) vs Warfarin

Recent studies have consistently shown that DOACs have more favorable efficacy and safety profiles compared to warfarin in patients with atrial fibrillation. Network meta-analyses have demonstrated that DOACs reduce the risk of major bleeding and intracranial hemorrhage more effectively than warfarin[4].

Market Analysis

Current Market Size and Growth

The global anticoagulants market, which includes warfarin, is expected to grow significantly. By 2024, the market is projected to reach $41.31 billion and is anticipated to expand to $89.50 billion by 2033, with a CAGR of 8.97% from 2025 to 2033[2].

Distribution Channels

Hospital pharmacies are expected to hold the highest share among distribution channels due to the risky nature of anticoagulant prescriptions, which often require thorough diagnosis and monitoring, typically conducted in hospital settings[5].

Regional Analysis

North America is currently a dominant region in the anticoagulants market, driven by the high prevalence of cardiovascular diseases and ongoing research and development initiatives. However, the Asia Pacific region is expected to witness the highest growth due to increasing disposable incomes and greater awareness of cardiovascular diseases[5].

Market Projections

Competitive Landscape

Despite the emergence of DOACs, warfarin remains a significant player in the market, particularly in regions where access to newer anticoagulants is limited. However, the market share of warfarin is expected to decline as DOACs continue to gain preference due to their superior safety profile and convenience[3][5].

Novel Oral Anticoagulants (NOACs) Impact

The development and widespread adoption of NOACs are driving the anticoagulants market. NOACs offer a more favorable risk-benefit profile compared to traditional anticoagulants like warfarin, with lower risks of major bleeding and intracranial hemorrhage. This shift is expected to continue, with ongoing clinical trials and research aimed at exploring new indications and enhancing the therapeutic efficacy of existing NOACs[3].

Challenges and Limitations

Generic Competition

Warfarin, being one of the earliest anticoagulants, faces significant competition from generic versions. This competition limits its revenue potential despite its continued use in certain clinical scenarios[5].

Monitoring Requirements

Warfarin requires regular monitoring of international normalized ratio (INR) levels, which can be a drawback compared to DOACs that do not require such monitoring. This complexity in management can affect patient compliance and healthcare resource utilization[4].

Future Outlook

Personalized Medicine

The trend towards personalized medicine, using genetic and biomarker data to tailor treatments, is expected to influence the anticoagulants market. While warfarin may not be the primary beneficiary of this trend, it highlights the evolving landscape in which anticoagulant therapies are being developed and prescribed[3].

Reversal Agents

The development of reversal agents for DOACs, such as idarucizumab for dabigatran and andexanet alfa for Factor Xa inhibitors, addresses a critical need for managing bleeding complications. This innovation further solidifies the position of DOACs in the market, potentially reducing the reliance on warfarin in certain cases[3].

Key Takeaways

• Clinical Trials: Warfarin remains effective but is often outperformed by DOACs in terms of safety and convenience.
• Market Size: The global anticoagulants market is projected to grow significantly, but warfarin's share is expected to decline.
• Distribution Channels: Hospital pharmacies dominate the distribution of anticoagulants.
• Regional Analysis: North America and Asia Pacific are key regions driving the market growth.
• Competitive Landscape: DOACs are gaining preference over traditional anticoagulants like warfarin.
• Future Outlook: Personalized medicine and the development of reversal agents are shaping the future of anticoagulation therapy.

FAQs

What are the main differences between warfarin and DOACs?

Warfarin requires regular INR monitoring and has a narrower therapeutic window compared to DOACs, which offer a more convenient dosing regimen and a superior safety profile in terms of reduced major bleeding risks.

How is the market for anticoagulants expected to grow?

The global anticoagulants market is expected to grow from $41.31 billion in 2024 to $89.50 billion by 2033, with a CAGR of 8.97% from 2025 to 2033.

Which regions are driving the growth of the anticoagulants market?

North America and the Asia Pacific region are driving the growth, with North America currently holding the highest market share and the Asia Pacific region expected to witness the highest growth due to increasing awareness and prevalence of cardiovascular diseases.

What impact do generic versions have on warfarin's market share?

Generic versions of warfarin limit its revenue potential despite its continued use, as they offer a cheaper alternative.

How does personalized medicine influence the anticoagulants market?

Personalized medicine, using genetic and biomarker data, is expected to enhance the therapeutic efficacy of anticoagulants, although it may not significantly benefit warfarin due to its traditional use and monitoring requirements.

Sources

1. Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation. JAMA, 2014.
2. Anticoagulants Market Analysis Growth Forecast Report 2025-2033. Renub Research.
3. Venous Thromboembolism Market Size to Reach USD 7.0 Billion by 2034. BioSpace.
4. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation. Circulation, 2022.
5. Anticoagulants Market Size, Share & Growth | Forecast Report, 2032. Fortune Business Insights.